(Q36497078)

14 August 2017

1 reference

title

The clinical implications of antiretroviral pharmacogenomics (English)

1 reference

14 August 2017

main subject

anti-retroviral agent

0 references

1 reference

2

Marta Boffito

1 reference

14 August 2017

3

Alan Winston

1 reference

14 August 2017

Julie Fox

1

1 reference

14 August 2017

language of work or name

1 reference

1 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

587-596

1 reference

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Risk factor analysis of hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Mitochondrial DNA variation in human evolution and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

P-glycoprotein and multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

The management of HIV-1 protease inhibitor pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

The influence of age and sex on the clearance of cytochrome P450 3A substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

The mechanisms that control intracellular penetration of the HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Clinical aspects of the MDR1 (ABCB1) gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Protein binding in antiretroviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Human UDP-glucuronosyltransferases: metabolism, expression, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Polymorphic variations in the expression of the chemical detoxifying UDP glucuronosyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Atazanavir for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Apolipoprotein E: far more than a lipid transport protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

HIV chemokine receptor inhibitors as novel anti-HIV drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

HIV evolution: CTL escape mutation and reversion after transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

Repair of mucosal damage induced by ethanol in the rat stomach. Effects of concentration, exposure period and prostaglandins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.4.587

21 January 2018

Identifiers

DOI

10.2217/14622416.7.4.587

1 reference

14 August 2017

1 reference